mRNA Therapeutics Market Size & Growth Forecast 2027–2036, By Segments (Type, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
mRNA Therapeutics Market size stood at USD 14.2 billion in 2026 and is predicted to grow at a 16.15% CAGR from 2027 to 2036, exceeding USD 63.46 billion by 2036. The industry revenue for 2027 is estimated at USD 16.13 billion.
Get more details on this report
Request Free Sample ReportmRNA Therapeutics Market Intelligence Snapshot
Regional Market Dynamics
- North America captured 42.79% of the market in 2026, supported by advanced biotechnology capabilities, established clinical research infrastructure, and efficient commercialization pathways for therapeutic development.
- Asia Pacific is projected to grow at a 19.15% CAGR, driven by expanding biopharmaceutical capacity, rising biologics investment, stronger translational research, and increasing adoption of advanced therapeutic platforms.
Segment Momentum
- Prophylactic applications held a 93.1% market share in 2026, supported by established preventive use, broad population targeting, scalable deployment, and alignment with public health delivery models.
- Hospitals & Clinics are experiencing the fastest growth because they provide the infrastructure for administration, patient monitoring, storage, and specialized care, enabling wider clinical adoption of mRNA therapeutics.
Market Expansion Drivers
- Expanding clinical trial activity accelerating commercialization of mRNA therapeutics across chronic disease applications.
- Advancements in mRNA delivery technologies improving therapeutic stability, safety, and large-scale manufacturing efficiency.
- Increasing biopharmaceutical partnerships strengthening investment in personalized mRNA-based therapeutic development pipelines.
Leading Market Participants
- Leading players in the mRNA therapeutics market include Moderna, Inc. (United States), BioNTech SE (Germany), Pfizer Inc. (United States), CureVac N.V. (Germany), Sanofi S.A. (France), GlaxoSmithKline plc (United Kingdom), AstraZeneca PLC (United Kingdom), Arcturus Therapeutics Holdings Inc. (United States), Ethris GmbH (Germany), CSL Seqirus (Australia).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 14.2 billion
- 2027 Estimated Market Size: USD 16.13 billion.
- Projected Market Size: USD 63.46 billion by 2036
- Growth Forecast: 16.15% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Prophylactic (Type) | Hospitals & Clinics (End-use) | Infectious Diseases (Application)
- Emerging Opportunity Segment: Therapeutic (Type) | Hospitals & Clinics (End-use) | Oncology (Application)
Market Growth Drivers and Industry Trends
Expanding clinical trial activity accelerating commercialization of mRNA therapeutics across chronic disease applications
Increasing clinical trial activity will drive the mRNA therapeutics market as researchers broaden the investigation of messenger RNA-based approaches beyond established applications into chronic and complex diseases. Clinical development is helping evaluate the ability of mRNA platforms to deliver therapeutic proteins, modulate biological pathways, and support disease-specific treatment strategies. As evidence from clinical programs accumulates, pharmaceutical developers are gaining greater opportunities to advance mRNA candidates through development and commercialization pathways.
Advancements in mRNA delivery technologies improving therapeutic stability, safety, and large-scale manufacturing efficiency
The mRNA therapeutics market is being strengthened by advances in delivery technologies that address important challenges associated with RNA stability, cellular uptake, and targeted administration. Improved delivery systems can protect mRNA molecules from degradation while enabling more efficient transport into intended cells, supporting therapeutic activity at appropriate sites. Progress in formulation and manufacturing processes is also helping developers establish more consistent production workflows and improve the scalability of mRNA-based products.
Increasing biopharmaceutical partnerships strengthening investment in personalized mRNA-based therapeutic development pipelines
Increasing collaboration across the biopharmaceutical sector will boost the mRNA therapeutics market by combining specialized capabilities in RNA research, delivery technologies, clinical development, and manufacturing. Partnerships can distribute development risks while providing access to complementary technologies and research expertise, encouraging broader investment in therapeutic pipelines. Personalized approaches are particularly supported by these collaborations because mRNA platforms can be designed around specific biological targets and disease characteristics.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding clinical trial activity accelerating commercialization of mRNA therapeutics across chronic disease applications | 2.00% | High | North America, Europe | High | Near Term |
| Advancements in mRNA delivery technologies improving therapeutic stability, safety, and large-scale manufacturing efficiency | 1.70% | Moderate | North America, Asia Pacific | High | Mid Term |
| Increasing biopharmaceutical partnerships strengthening investment in personalized mRNA-based therapeutic development pipelines | 1.30% | Moderate | Asia Pacific, North America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the mRNA therapeutics market at 42.79% in 2026, reflecting its mature biotechnology ecosystem, advanced pharmaceutical research capabilities, and strong infrastructure for developing innovative nucleic acid-based therapies. The region has a well-developed clinical research environment and established expertise in mRNA design, delivery technologies, manufacturing, and regulatory development. Continued investment in next-generation vaccines and therapeutic applications is broadening the potential use of mRNA platforms beyond infectious diseases, including oncology and other complex medical conditions, thereby reinforcing regional market leadership.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region, supported by expanding biopharmaceutical manufacturing capacity, increasing healthcare investment, and growing interest in advanced therapeutic platforms. Governments and healthcare institutions across the region are strengthening biotechnology capabilities, while domestic research activity and technology adoption are supporting the development of localized mRNA production and clinical applications. Improvements in healthcare infrastructure and rising demand for innovative treatments are further encouraging investment in mRNA technologies, positioning Asia Pacific as an increasingly important growth center for the market.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Manufacturing Technology ExcellenceGermany supports the mRNA therapeutics market through advanced biopharmaceutical production and process optimization capabilities. Industry participants focus on scalable manufacturing, quality assurance, and research collaborations that accelerate therapeutic development.
France 🇫🇷
Research Collaboration NetworkFrance advances the mRNA therapeutics market through collaboration between biotechnology firms, research institutes, and healthcare organizations. Development efforts prioritize innovative therapeutic candidates supported by efficient clinical research ecosystems.
Italy 🇮🇹
Specialized Development CapabilitiesItaly contributes to the mRNA therapeutics market through pharmaceutical research, contract development, and specialized manufacturing expertise. Italian organizations focus on supporting therapeutic innovation while reinforcing quality-driven production processes.
Japan 🇯🇵
Precision Therapeutic DevelopmentJapan's mRNA therapeutics market emphasizes targeted treatment development supported by strong pharmaceutical research capabilities. Organizations invest in delivery technologies and product quality to address complex therapeutic applications across multiple disease areas.
South Korea 🇰🇷
Biotech Commercialization DriveSouth Korea is expanding the mRNA therapeutics market through biotechnology investment and partnerships across research and manufacturing. Companies focus on strengthening development pipelines while enhancing production flexibility for future therapeutic programs.
United States 🇺🇸
Platform Innovation CenterThe U.S. mRNA therapeutics market is characterized by continuous investment in platform technologies, clinical development, and manufacturing scale-up. Companies in the U.S. prioritize expanding therapeutic applications while strengthening production capabilities for diverse disease targets.
Segment Leadership and Growth Trends
mRNA Therapeutics Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Prophylactic (Largest Segment) vs Therapeutic (Fastest-Growing Segment)
The prophylactic segment dominated the mRNA therapeutics market in 2026, accounting for a 93.1% share, supported by the strong role of mRNA-based approaches in preventing infectious diseases through rapid and targeted immune responses. The segment benefits from the ability of mRNA platforms to facilitate antigen production within cells while offering development flexibility and scalable manufacturing potential. Continued emphasis on disease prevention, vaccine innovation, and adaptable therapeutic platforms further reinforces the leading position of prophylactic applications.
Therapeutic applications are gaining momentum as mRNA technology expands beyond preventive immunization into treatments designed to address a broader range of diseases. Advances in personalized medicine, cancer-focused applications, protein replacement, and regenerative approaches are supporting interest in therapeutic mRNA, while improvements in delivery technologies and formulation stability are helping broaden its potential clinical use.
End-use Segment Analysis: Hospitals & Clinics (Largest & Fastest-Growing Segment)
Hospitals & clinics held the largest share of the mRNA therapeutics market in 2026, accounting for 48.08%, while also representing the fastest-growing end-use segment. Their leading position reflects the concentration of specialized healthcare infrastructure, clinical expertise, diagnostic capabilities, and treatment administration within these settings. Hospitals and clinics are particularly important for emerging mRNA-based therapies because their multidisciplinary care environments can support advanced treatment protocols, patient monitoring, and the integration of innovative therapeutic approaches into clinical practice.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Prophylactic, Therapeutic | Prophylactic | Therapeutic |
| End-use | Hospitals & Clinics, Research Organizations, Others | Hospitals & Clinics | Hospitals & Clinics |
| Application | Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, Others | Infectious Diseases | Oncology |
Competitive Landscape and Market Positioning
Key companies in the mRNA therapeutics market:
1. Moderna Inc. (United States)
2. BioNTech SE (Germany)
3. Pfizer Inc. (United States)
4. CureVac N.V. (Germany)
5. Sanofi S.A. (France)
6. GlaxoSmithKline plc (United Kingdom)
7. AstraZeneca PLC (United Kingdom)
8. Arcturus Therapeutics Holdings Inc. (United States)
9. Ethris GmbH (Germany)
10. CSL Seqirus (Australia)
The mRNA therapeutics market is rapidly advancing through development of next-generation genetic medicine platforms aimed at addressing complex diseases. Continuous innovation in delivery systems and molecular design is improving therapeutic precision and effectiveness. The market is increasingly driven by breakthroughs in RNA-based medicine technologies.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Moderna Inc. (United States) | |||||||
| BioNTech SE (Germany) | |||||||
| Pfizer Inc. (United States) | |||||||
| CureVac N.V. (Germany) | |||||||
| Sanofi S.A. (France) | |||||||
| GlaxoSmithKline plc (United Kingdom) | |||||||
| AstraZeneca PLC (United Kingdom) | |||||||
| Arcturus Therapeutics Holdings Inc. (United States) | |||||||
| Ethris GmbH (Germany) | |||||||
| CSL Seqirus (Australia). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Oxford Nanopore Technologies and Lonza | May-26 | Oxford Nanopore Technologies and Lonza launched a joint quality control solution specifically designed to modernize and accelerate GMP testing for mRNA therapeutics. This collaborative initiative aims to streamline analytical workflows and improve the efficiency of manufacturing release testing, ultimately facilitating faster development and more reliable production cycles for mRNA-based medical products. |
| ParcelBio | May-26 | Programmable mRNA startup ParcelBio secured $13 million in new funding to advance its proprietary platform. The capital is designated for extending the expression duration of mRNA and expanding therapeutic applications into chronic disease treatments, marking a strategic effort to evolve beyond traditional vaccine-focused mRNA modalities. |
| Reprogram Biosciences Inc. | May-26 | Preclinical oncology firm Reprogram Biosciences Inc. closed a seed financing round, reaching $6 million in total funding since its 2025 inception. The investment provides the necessary capital to advance its early-stage pipeline focused on mRNA-based therapeutics for solid tumors, supporting the continued exploration of novel mRNA-driven cancer treatment approaches. |
| Eli Lilly | Apr-26 | Eli Lilly entered a definitive agreement to acquire Kelonia Therapeutics in a transaction valued at up to $7 billion. This acquisition, featuring a $3.25 billion upfront payment, secures Kelonia’s proprietary in vivo gene placement system (iGPS), designed to enable the production of CAR-T cells directly within the patient’s body, thereby bypassing complex and costly ex vivo manufacturing requirements. |
| ONI | Feb-26 | ONI launched LNP PREP on its Aplo Flow platform, offering an automated, single-particle analysis workflow for lipid nanoparticle characterization. By integrating programmable fluidics with advanced microscopy, the solution enables more precise and scalable characterization, directly addressing critical bottlenecks in the development and manufacturing of mRNA delivery systems. |
| Samsung Biologics | Jan-26 | Samsung Biologics America acquired a former GSK biologics facility for $280 million, marking the company’s strategic entry into the U.S. biopharmaceutical manufacturing market. The acquisition significantly expands its manufacturing footprint and enhances large-scale production capabilities, reinforcing its position as a major service provider in the global biologics and mRNA-related manufacturing ecosystem. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
mRNA Therapeutics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Development Stage | Preclinical, Phase I, Phase II, Phase III, Commercialized |
| Delivery Route | Intramuscular, Intravenous, Intradermal, Intranasal, Other Routes |
| Target Population | Adult, Pediatric, Geriatric, Mixed-Age Population |
mRNA Therapeutics Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| mRNA Therapeutics Commercialization Roadmap |
|
| Delivery Technology Opportunity Assessment |
|
| Strategic Partnership Opportunity Mapping |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the mRNA therapeutics market?
What is the projected value of the mRNA therapeutics industry by 2036?
How are expanding clinical trials shaping commercialization pathways for mRNA therapeutics?
What is driving scalability and investment confidence in mRNA therapeutic development?
Why does the prophylactic segment dominate the mRNA therapeutics market?
Why are Hospitals & Clinics the fastest-growing end-use segment in the mRNA therapeutics market?
Why does North America hold the largest share of the mRNA therapeutics market?
What factors are driving Asia Pacific's growth in the mRNA therapeutics market?
Who are the leading players in the mRNA therapeutics landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization